WithdrawnPhase 2

Bone Healing Accelerant (BHA) Versus Autologous Bone Grafting (ABG) for Hindfoot or Ankle Arthrodesis

Stopped: study never started and is on hold until further notice

0Started 2024-03

Plain-language summary

This study is being conducted to demonstrate the safety and effectiveness of Bone Healing Accelerant (BHA) product when applied to the joint space of the ankle of hindfoot (the section of the foot immediately below the ankle joint) during fusion surgery. It is hypothesized that by 6 months, the number of subjects with successful bone fusion will be greater in the BHA-treated group compared to subjects treated with standard of care alone.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Tibiotalar (ankle)
✓. Talocalcaneal (subtalar)
✓. Talonavicular
✓. Calcaneocuboid
✓. Double hindfoot (e.g., talonavicular and talocalcaneal joints)
✓. Triple hindfoot (subtalar, talonavicular and calcaneocuboid joints

What they're measuring

Successful Radiographic Fusion

Timeframe: 24 weeks

Trial details

NCT IDNCT06258499

SponsorCarmell Therapeutics Corporation

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-09

View on ClinicalTrials.gov More Foot Deformities trials